MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

Search

Smith & Nephew PLC ADR

Затворен

33.06 0.15

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

32.88

Максимум

33.24

Ключови измерители

By Trading Economics

Приходи

100M

296M

Продажби

4.7M

3B

P/E

Средно за сектора

29.571

78.892

Дивидентна доходност

2.3

Марж на печалбата

9.895

Служители

17,000

EBITDA

6.5M

723M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+8.2% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.30%

2.38%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

585M

14B

Предишно отваряне

32.91

Предишно затваряне

33.06

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Smith & Nephew PLC ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.12.2025 г., 22:03 ч. UTC

Значими двигатели на пазара

Mining Stocks Slip Near the End of Stellar Year

29.12.2025 г., 15:57 ч. UTC

Значими двигатели на пазара

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29.12.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Decline; Yen in Focus -- Market Talk

29.12.2025 г., 23:38 ч. UTC

Придобивния, сливания и поглъщания

Manus: Will Continue to Operate From Singapore

29.12.2025 г., 23:38 ч. UTC

Придобивния, сливания и поглъщания

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29.12.2025 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms: Will Integrate Manus Service Into Products

29.12.2025 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms: Will Continue to Operate, Sell Manus Service

29.12.2025 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29.12.2025 г., 23:35 ч. UTC

Придобивния, сливания и поглъщания

Manus to Join Meta Platforms

29.12.2025 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Origin: Raise Values Kraken at US$8.65 Billion

29.12.2025 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Origin: Octopus Targeting Kraken Separation by Mid 2026

29.12.2025 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29.12.2025 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29.12.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Origin's Kraken Stake to Remain at 22.7%

29.12.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29.12.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29.12.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Origin: Additional Interest Offsets Dilution From Raise

29.12.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29.12.2025 г., 21:27 ч. UTC

Придобивния, сливания и поглъщания

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29.12.2025 г., 20:22 ч. UTC

Пазарно говорене

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29.12.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29.12.2025 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29.12.2025 г., 17:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Smith & Nephew PLC ADR Прогноза

Ценова цел

By TipRanks

8.2% нагоре

12-месечна прогноза

Среден 35.75 USD  8.2%

Висок 37.5 USD

Нисък 34 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Smith & Nephew PLC ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

2 ratings

0

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

26.64 / 28.37Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat